Scandinavian Journal of Urology and Nephrology · 1995 · 35 citations · 16 references
MedicineOncologyPathologyNeoplasiaTumor PathologyTumor ProgressionBladder CancerCancer Molecular PathologyMalignant NeoplasmsTumor ClassificationUrologic Cancer DiagnosisUrothelial CarcinomaEndoscopic Cancer ResectionImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingP53 MutationPrognostic Factors AnalysisTp53 Mutations
Approximately 1/3 of T1 bladder cancers treated by endoscopic resection alone will progress. Prognostic factors are needed to help selecting appropriate treatment for these tumors. The purpose of the present investigation was to study the relation between p53 nuclear overexpression and disease progression. Tumors from 59 patients were studied by means of immunohistochemical nuclear staining. Forty tumors showed p53 nuclear overexpression while 19 tumors scored negative for mutations. We could not demonstrate any correlation between mutations of the p53 protein and tumor grading. p53 nuclear overexpression was not related to disease progression.
16
Participation of p53 protein in the cellular response to DNA damage.
Michael B. Kastan, Onyinye Onyekwere, D Sidransky et al. · PubMed · 1991 · 3.8K citations
p21 is a universal inhibitor of cyclin kinases
Yue Xiong, Gregory J. Hannon, Hui Zhang et al. · Nature · 1993 · 3.4K citations
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Toshiyuki Miyashita, Stanisław Krajewski, Maryla Krajewska et al. · PubMed · 1994 · 2.2K citations
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Elisheva Yonish-Rouach, Dalia Resnftzky, Joseph Lotem et al. · Nature · 1991 · 2.1K citations
Medicine, Hematology, Oncology +13
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
S Waga, Gregory J. Hannon, David Beach et al. · Nature · 1994 · 1.7K citations